Navigation Links
OncoGenex Pharmaceuticals to Present at RBC Capital Markets' Healthcare Conference
Date:3/1/2010

account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='85801917';s.tl(this,'o','ExternalLink');" target='_blank' href="http://ir.oncogenex.com">http://ir.oncogenex.com. A webcast replay will be available approximately two hours after the call and will be archived for 30 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase 3 trials in castrate resistant prostate cancer in 2010, and a third Phase 3 trial in non-small cell lung cancer in early 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
2. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
3. OncoGenex Reports Third Quarter 2009 Financial Results
4. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
5. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
6. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
7. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
8. OncoGenex Reports Second Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
11. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
(Date:9/18/2014)... 2014 OMICS Group International invites ... participate in the ‘Open Access Week’ by actively ... OMICS Group Pharma Journals from 20-26th October, ... fastest emerging Sciences, accelerating with a tremendous speed ... the globe. The industry is gearing with innovation ...
(Date:9/18/2014)... pretty expensive. Now a team led by an engineer ... of designs that will let scientists slash the cost ... pump. , Syringe pumps are used to dispatch precise ... chemicals in a reaction. They can also cost hundreds ... his team of Michigan Tech students published the library ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Doing science just got cheaper -- and faster 2
... Inc. , a biotechnology company focused on the development ... diseases, has entered into an in-vitro diagnostics patent license ... firm. , ,Under the agreement, which will be effective ... enzymes in its products. Prodesse also receives the authority ...
... Allis, Wis. - After conducting a lengthy financial ... Healthcare has announced the resignations of three executives, ... errors in its financial statements. , ,The stock market ... as the value of Merge shares declined by 41 ...
... - The relocation of one area biotech has resulted in ... take it even higher. , ,And while GWC Technologies ... interactions on bioarrays, is not yet in the penthouse, the ... high-tech product development, according to president and CEO Tim Burland. ...
Cached Biology Technology:Merge execs step down following investigation 2Merge execs step down following investigation 3Madison biotech continues its climb 2Madison biotech continues its climb 3Madison biotech continues its climb 4
(Date:9/18/2014)... The ability to acquire and creatively manipulate spoken language ... over the past 6 million years of human evolution ... is the best candidate gene we now have," says ... LMU. In his efforts to understand the molecular biological ... step forward. The results of his latest study, undertaken ...
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
(Date:9/18/2014)... colleagues have built the first smartphone app that ... behavioral trends. In other words, your smartphone knows ... don,t -- and how that affects you. , ... depression and loneliness to their academic performance, also ... for example, to monitor mental health, trigger intervention ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... Forest Service scientists have found that prescribed fires with the ... oak ecosystems. Forest Service researchers are helping land ... oak regeneration from acorns is a concern. "Acorns ... the most part protected from fire," says Cathryn Greenberg, Forest ...
... in JoVE , the Journal of Visualized ... spider silk from bacteria. The procedure presented in the ... standardizing a key step known as "post-spin." In this ... to increase fiber strength. These mechanical improvements produce uniform ...
... Waterlogged protein . . . Proteins, biological ... our bodies, are known to rely heavily on the ... remained unclear. In a paper published in Physical Review ... new evidence that suggests water is even more involved ...
Cached Biology News:Leaf litter and soil protect acorns from prescribed fire 2The future of biomaterial manufacturing: Spider silk production from bacteria 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2012 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2012 3
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Human FADD Affinity Purified Polyclonal Ab...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: